Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

FDA approves J&J's Tremfya for psoriasis

July 14, 2017 7:11 PM UTC

FDA approved Tremfya guselkumab (CNTO 1959) from Johnson & Johnson (NYSE:JNJ) to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Spokesperson Brian Kenney told BioCentury that J&J expects to launch Tremfya within 2 weeks at an annual wholesale acquisition cost (WAC) of $58,100.

Tremfya is a human HuCAL mAb targeting the p19 subunit of IL-23...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Johnson & Johnson

MorphoSys AG

BCIQ Target Profiles

Interleukin-23 (IL-23)